GGrantIndex
Sort

17,828 grants matching crispr

Bioengineering adipocytes for cancer therapy

$643,221
Nadav Ahituv · University Of California, San Francisco · R01 · FY2024 · CA

The roles of p53 in embryonic stem cells

$643,215
Jing Huang · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Characterizing non-coding somatic and germline variant interactions in ovarian cancer

$643,149
Simon Andrew Gayther · Cedars-Sinai Medical Center · R01 · FY2023 · CA

Noninvasive High-Resolution Mapping of HCC Tumor Biology Predictive of Malignancy

$643,066
Kejia Cai · University Of Illinois At Chicago · R01 · FY2025 · CA

Transcriptional Mechanisms of Human Insulin Resistance

$642,923
Evan D Rosen · Beth Israel Deaconess Medical Center · R01 · FY2020 · DK

Development and maintenance of chronic toxoplasmosis

$642,884
Sebastian Lourido · Whitehead Institute For Biomedical Res · R01 · FY2024 · AI

Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics

$642,817
Martin Kampmann · University Of California, San Francisco · R01 · FY2019 · AG

Project 3 (Mercola)

$642,755
Mark Mercola · Stanford University · P01 · FY2019 · HL

The biogenesis and functions of pre-meiotic small RNAs in male reproductive development in maize

$642,737
Blake C Meyers · University Of California At Davis · R01 · FY2024 · GM

Immune receptor degradation for immune evasion of head and neck cancer

$642,488
Dohun Pyeon · Henry Ford Health + Michigan State University Health Sciences · R01 · FY2025 · DE

Engineering T Cell Adoptive Therapy for Glioblastoma

$642,482
Gavin Peter Dunn · Massachusetts General Hospital · R01 · FY2025 · NS

Deciphering unintended large gene modifications in gene editing for sickle cell disease

$642,458
Gang Bao · Rice University · R01 · FY2025 · HL

Project 1 - Modulation of Tolerance and Autoimmunity by Inhibitory Receptors

$642,410
Arlene H Sharpe · University Of Pittsburgh At Pittsburgh · P01 · FY2025 · AI

Development of novel approaches for gene editing therapies of cystic fibrosis

$642,400
Jianming Qiu · University Of Kansas Medical Center · R01 · FY2024 · HL

** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** PLANT DISEASES ARE SIGNIFICANT THREATS TO AGRICULTURE. MONITORING IS A CRUCIAL STEP IN DISEASE PREVENTION AND REQUIRES AFFORDABLE, SENSITIVE, AND SPECIFIC DIAGNOSTIC TESTS. ESPECIALLY FOR EMERGING PATHOGENS, TESTS NEED TO BE DEVELOPED QUICKLY TO DETECT NOVEL VARIANTS, STRAINS, RACES, OR SPECIES. CRISPR-BASED DIAGNOSTIC TOOLS ARE ECONOMICAL, SCALABLE, LOW COST, AND CAPABLE OF BEING USED IN THE FIELD ISOTHERMALLY AND ASSESSED VIA LATERAL FLOW DEVICES. OUR SPECIFIC GOAL IS TO DEVELOP AN INTEGRATED COMPUTATIONAL AND MOLECULAR WORKFLOW FOR DEVELOPING RAPID CRISPR-BASED DIAGNOSTICS. SPECIFIC OBJECTIVES INCLUDE, AIM 1: EXPAND UPON AN EXISTING PYTHON ALGORITHM TO GENERALIZE USE OF WHOLE GENOME SEQUENCES FOR DESIGN OF CRISPR DIAGNOSTICSFOR MAJOR PLATFORMS; AIM 2: DEMONSTRATE PROOF-OF-CONCEPT BY USING TWO PATHOGEN GROUPS WITH VAST GENOMIC RESOURCES AND ECONOMIC IMPORTANCE; AND AIM 3: DEVELOP WEB-BASED RESOURCES AND PROTOCOLS AS WELL AS PRESENT AT WORKSHOPS. TWO WELL-STUDIED PATHOGEN GROUPS OF ECONOMIC IMPORTANCE AND WITH VAST GENOMIC RESOURCES WILL BE USED FOR PROOF-OF-CONCEPT. OUR GOALS ARE HIGHLY RELEVANT TO THE PROGRAM PRIORITIES 1. PROVIDING NOVEL MEANS OF DETECTION AND DIAGNOSTICS OF TRANSBOUNDARY, EMERGING, RE-EMERGING, OR INVASIVE DISEASES ASSOCIATED WITH PLANT PRODUCTION SYSTEMS; AND 2. PROVIDING NOVEL APPROACHES FACILITATING A RAPID RESPONSE TO, AND RECOVERY FROM, PESTS AND DISEASES THAT POSE LARGE-SCALE BIOSECURITY THREATS TO PLANT PRODUCTION, INCLUDING EXISTING AND IMMINENT THREATS TO U.S. AGRICULTURAL PRODUCTION AND FOOD SUPPLY SYSTEMS.

$642,301
Oregon State University · · FY2023 · National Institute of Food and Agriculture

Modulating intrinsic beta cell stress to block diabetes pathogenesis

$642,131
Feroz R Papa · University Of California, San Francisco · R01 · FY2024 · DK

Sequencing Familial Lung Cancer

$642,057
Christopher I. Amos · Baylor College Of Medicine · U01 · FY2022 · CA

Sequencing Familial Lung Cancer

$642,057
Christopher I. Amos · Baylor College Of Medicine · R01 · FY2023 · CA

Emerging multidrug resistance mechanisms in Campylobacter

$641,884
Qijing Zhang · Iowa State University · R01 · FY2020 · AI

Aging and rejuvenation: An ant model to study the regulation of longevity

$641,625
Danny F Reinberg · New York University School Of Medicine · R01 · FY2021 · AG

Employing CRISPR inactivation screening and in vivo models towards improving treatments for SCLC

$641,606
David Macpherson · Fred Hutchinson Cancer Research Center · U01 · FY2020 · CA

Aging and rejuvenation: An ant model to study the regulation of longevity

$641,567
Danny F Reinberg · New York University School Of Medicine · R01 · FY2020 · AG

Aging and rejuvenation: An ant model to study the regulation of longevity

$641,511
Danny F Reinberg · New York University School Of Medicine · R01 · FY2019 · AG

Development of Cre driver rat strains for creating conditional and physiologically relevant models of human diseases

$641,298
Ruby Yanru Chen-Tsai · Applied Stemcell, Inc. · R44 · FY2018 · GM

Development of Cre driver rat strains for creating conditional and physiologically relevant models of human diseases

$641,298
Ruby Yanru Chen-Tsai · Applied Stemcell, Inc. · R44 · FY2017 · GM